Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease

The role of aspirin for primary prevention in older adults with chronic kidney disease (CKD) is unclear. Therefore, post hoc analysis of the randomized controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Kidney Int
Main Authors: Wolfe, Rory, Wetmore, James B., Woods, Robyn L., McNeil, John J., Gallagher, Hugh, Roderick, Paul, Walker, Rowan, Nelson, Mark R., Reid, Christopher M., Shah, Raj C., Ernst, Michael E., Lockery, Jessica E., Tonkin, Andrew M., Abhayaratna, Walter P., Gibbs, Peter, Wood, Erica M., Mahady, Suzanne E., Williamson, Jeff D., Donnan, Geoffrey A., Cloud, Geoffrey C., Murray, Anne M., Polkinghorne, Kevan R.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2020
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7957958/
https://ncbi.nlm.nih.gov/pubmed/32920022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.kint.2020.08.011
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים